{
    "id": "0759",
    "question": "A 33-year-old woman presents to the clinic for follow-up of her AIDS treatment with highly active anti-retroviral therapy (HAART). She is in good spirits and has been fully compliant with her medications and clinic visits. Other medications include prophylactic co-trimoxazole. Recent blood studies show the following:\nHemoglobin (Hb%)  11 g/dL\nMean corpuscular volume (MCV)  80 fl\nReticulocyte count 0.5%\nErythrocyte count 2 x 106/mm3\nLeucocyte count 700/mm3\nNeutrophils 40%\nPlatelet count 20,000/mm3\nAssays also show a decreased viral DNA and mRNA burden, as well as a significantly diminished viral load. To avoid modifying the effective anti-retroviral therapy, she is started on a \u2018blood improving\u2019 medication. Thirty minutes after the first dose, the patient develops difficulty breathing, severe muscle pain, and vomiting. Her pulse rate is 120/min and the blood pressure is 80/50 mm Hg. Which of the following medications was most likely administered to the patient?",
    "options": {
        "A": "Interleukin 3",
        "B": "Platelet-derived growth factor",
        "C": "Sargramostim",
        "D": "Thrombopoietin"
    },
    "answer": "C",
    "predict": "{\"step_by_step_thinking\": \"To determine which medication was administered to the patient, let's analyze the symptoms and lab results provided. The patient is a 33-year-old woman with AIDS who is in good spirits and has been fully compliant with her medications and clinic visits. Her recent blood studies show a low hemoglobin level (11 g/dL), low platelet count (20,000/mm^3), and a significantly diminished viral load. The patient develops difficulty breathing, severe muscle pain, and vomiting 30 minutes after receiving a medication, which suggests an adverse reaction. Given the options provided, we need to consider the potential side effects of each medication. Interleukin 3 (IL-3) is a growth factor that stimulates the proliferation of hematopoietic cells, but it is not commonly associated with severe adverse reactions. Platelet-derived growth factor (PDGF) is involved in the regulation of cell growth and division, but it is not typically linked to the symptoms described. Sargramostim is a granulocyte-macrophage colony-stimulating factor (GM-CSF) that stimulates the production of white blood cells, which could potentially cause an adverse reaction. Thrombopoietin is a hormone that regulates the production of platelets, but it is not commonly associated with the symptoms described. Considering the severe muscle pain and difficulty breathing, the most likely medication administered to the patient is Sargramostim, which can cause severe adverse reactions, including anaphylaxis, respiratory distress, and muscle pain.\", \"answer_choice\": \"C\"}",
    "snippets": [
        {
            "id": "Pharmacology_Katzung_5336",
            "title": "Pharmacology_Katzung",
            "content": "Sharon Safrin, MD A 35-year-old white woman who recently tested seropositive for both HIV and hepatitis B virus surface antigen is referred for evaluation. She is feeling well overall but reports a 25-pack-year smoking history. She drinks 3\u20134 beers per week and has no known medication allergies. She has a history of heroin use and is currently receiving methadone. Physical examination reveals normal vital signs and no abnormalities. White blood cell count is 5800 cells/mm3 with a normal differential, hemoglobin is 11.8 g/dL, all liver tests are within normal limits, CD4 cell count is 278 cells/mm3, and viral load (HIV RNA) is 110,000 copies/mL. What other laboratory tests should be ordered? Which antiretroviral medica-tions would you begin?"
        },
        {
            "id": "Pharmacology_Katzung_5664",
            "title": "Pharmacology_Katzung",
            "content": "Philip J. Rosenthal, MD A 5-year-old American girl presents with a 1-week history of intermittent chills, fever, and sweats. She had returned home 2 weeks earlier after leaving the USA for the first time to spend 3 weeks with her grandparents in Nigeria. She received all standard childhood immunizations, but no additional treat-ment before travel, since her parents have returned to their native Nigeria frequently without medical consequences. Three days ago, the child was seen in an outpatient clinic and diagnosed with a viral syndrome. Examination reveals a lethargic child, with a temperature of 39.8\u00b0C (103.6\u00b0F) and splenomegaly. She has no skin rash or lymphadenopathy. Ini-tial laboratory studies are remarkable for hematocrit 29.8%, platelets 45,000/mm3, creatinine 2.5 mg/dL (220 \u03bcmol/L), and mildly elevated bilirubin and transaminases. A blood smear shows ring forms of Plasmodium falciparum at 1.5% parasit-emia. What treatment should be started?"
        },
        {
            "id": "First_Aid_Step2_465",
            "title": "First_Aid_Step2",
            "content": "CD4+ count: Indicates the degree of immunosuppression; guides therapy and prophylaxis and helps determine prognosis. Viral load: May predict the rate of disease progression; provides indications for treatment and gauges response to antiretroviral therapy. \u25a0In acute HIV (acute infection/seroconversion, acute retroviral syndrome), the initial infection is often asymptomatic, but patients may also present with mononucleosis-like or f ulike symptoms (e.g., fever, lymphadenop ACUTE LATENT IMMUNODEFICIENCY Acute symptoms Opportunistic infections and malignancies CD4 lymphocytes Anti-p24 antibodies Anti-gp120 antibodies Virus, p24 antigen FIGURE 2.8-6. Time course of HIV infection. (Adapted, with permission, from Levinson W, Jawetz E. Medical Microbiology and Immunol ogy: Examination & Board Review, 6th ed. New York: McGraw-Hill, 2000: 276.) athy, maculopapular rash, pharyngitis, diarrhea, nausea/vomiting, weight loss, headache)."
        },
        {
            "id": "Pediatrics_Nelson_2637",
            "title": "Pediatrics_Nelson",
            "content": "Initiation of therapy (see Table 125-3) is recommended for infants less than 12 months of age regardless of symptoms of HIV disease or HIV RNA level. Initiation of therapy is recommended for all children 1 to 5 years of age with AIDS or significant HIV-related symptoms or CD4 below 25% (clinical category C or most clinical category B) regardless of symptoms or HIV RNA level. For children older than 5 years with AIDS or significant HIV-related symptoms, CD4 count below 350/mm3 should be treated. Indications for treatment of adolescents and adults include CD4 cell count less than 200 to 350/mm3 or plasma HIV RNA levels above 55,000 copies/mL. Combination therapy with highly active antiretroviral therapy (HAART) is recommended based on the risk of disease progression as determined by CD4 percentage or count and plasma HIV RNA copy number; the potential benefits"
        },
        {
            "id": "Pathology_Robbins_1080",
            "title": "Pathology_Robbins",
            "content": "Effect of Anti-Retroviral Drug Therapy on the Course of HIV Infection The advent of new drugs that target the viral reverse transcriptase, protease, and integrase enzymes has changed the clinical face of AIDS. When a combination of at least three effective drugs is used in a motivated, compliant patient, HIV replication is reduced to below the threshold of detection (<50 RNA copies/mL) and remains there as long as the patient adheres to therapy. Once the virus is suppressed, the progressive loss of CD4+ T cells is halted, and the peripheral CD4+ T-cell count slowly increases, often returning to a normal level. With the use of these drugs, the annual death rate from AIDS in the United States has decreased from a peak of 16 to 18 per 100,000 individuals in 1995\u20131996 to less than 4 per 100,000. Many AIDS-associated disorders, such as opportunistic infections with http://ebooksmedicine.net"
        },
        {
            "id": "First_Aid_Step2_468",
            "title": "First_Aid_Step2",
            "content": "Evaluation for acute retroviral syndrome (acute HIV) should include HIV RNA PCR (viral load); ELISA may be . Initiate antiretroviral therapy for the following: (1) symptomatic patients (i.e., those with AIDS-defning illness) regardless of CD4+ count or viral load; (2) asymptomatic patients with a CD4+ count < 350; (3) pregnant patients; and (4) those with specifc HIV-related conditions (e.g., HIV-associated nephropathy). The initial regimen should generally consist of some combination of two nucleoside/nucleotide reverse transcriptase inhibitors (RTIs) plus either one non-nucleoside RTI (NNRTI) or one protease inhibitor. The most important principle is to select multiple medications (usually at least three) in order to achieve durable treatment response and limit the emergence of resistance. The choice of regimen depends on drug-drug interactions, drug tolerance, patient adherence, and comorbid conditions (e.g., hyperlipidemia, refux). Monotherapy/dual therapy should not be used."
        },
        {
            "id": "Pharmacology_Katzung_5543",
            "title": "Pharmacology_Katzung",
            "content": "Combination antiviral therapy against both HIV and hepa-titis B virus (HBV) is indicated in this patient, given the high viral load and low CD4 cell count. However, the use of methadone and possibly excessive alcohol consumption necessitate caution. Tenofovir plus emtricitabine (two nucle-oside/nucleotide reverse transcriptase inhibitors) would be excellent choices as the NRTI \u201cbackbone\u201d of a fully sup-pressive regimen, since both are active against HIV-1 and HBV, do not interact with methadone, and are available in a once-daily, fixed-dose combination. A strand inhibitor such as raltegravir or dolutegravir, or the boosted combina-tion of darunavir/ritonavir could be added. There are other alternatives as well. Prior to initiation of this regimen, renal and liver function should be checked, HBV DNA level should be assessed, the patient should be screened for Hepa-titis A and HCV infection, and a bone mineral density test should be considered. Pregnancy should be ruled out, and the"
        },
        {
            "id": "Pharmacology_Katzung_7019",
            "title": "Pharmacology_Katzung",
            "content": "Her social history is significant for alcohol use (three to four glasses of wine/night). Her vital signs include the following: temperature 99.8\u00b0F, blood pressure 132/64 mm Hg, pulse 78 bpm, and respiratory rate 15/min. On physical examination, she had left upper abdominal tenderness with evidence of hepatomegaly and mild scleral icterus. Laboratory data revealed the following: alanine aminotransferase, 527 IU/L (normal 10\u201335 IU/L); aspartate aminotransferase, 425 IU/L (normal < 35 IU/L); and bilirubin, 2.9 mg/dL (normal 0.1\u20130.3 mg/dL). What medications do OTC cold and flu preparations typically contain? Which of the OTC medications might have contrib-uted to the patient\u2019s current symptoms? KH, a 55-year-old woman, presents to the emergency department with nausea, vomiting, and complaints of new-onset flu symptoms over the past several days. Her past medical history is significant for allergic rhinitis and chronic lower back pain secondary to a work-related fall 2 years ago. Her"
        },
        {
            "id": "Pharmacology_Katzung_3614",
            "title": "Pharmacology_Katzung",
            "content": "A 25-year-old woman who has been on a strict vegan diet for the past 2 years presents with increasing numbness and paresthesias in her extremities, generalized weakness, a sore tongue, and gastrointestinal discomfort. Physical examina-tion reveals a pale woman with diminished vibration sen-sation, diminished spinal reflexes, and extensor plantar reflexes (Babinski sign). Examination of her oral cavity reveals atrophic glossitis, in which the tongue appears deep red in color and abnormally smooth and shiny due to atro-phy of the lingual papillae. Laboratory testing reveals a mac-rocytic anemia based on a hematocrit of 30% (normal for women, 37\u201348%), a hemoglobin concentration of 9.4 g/dL, an erythrocyte mean cell volume (MCV) of 123 fL (nor-mal, 84\u201399 fL), an erythrocyte mean cell hemoglobin con-centration (MCHC) of 34% (normal, 31\u201336%), and a low reticulocyte count. Further laboratory testing reveals a normal serum folate concentration and a serum vitamin B12 (cobalamin) concentration"
        },
        {
            "id": "Pharmacology_Katzung_4230",
            "title": "Pharmacology_Katzung",
            "content": "JP is a 33-year-old woman who presents with complaints of fatigue requiring daytime naps, weight gain, cold intoler-ance, and muscle weakness for the last few months. These complaints are new since she used to always feel \u201chot,\u201d noted difficulty sleeping, and could eat anything that she wanted without gaining weight. She also would like to become preg-nant in the near future. Because of poor medication adherence to methimazole and propranolol, she received radioactive iodine (RAI) therapy, developed hypothyroidism, and was started on levothyroxine 100 mcg daily. Other medications include calcium carbonate three times daily to \u201cprotect her bones\u201d and omeprazole for \u201cheartburn.\u201d On physical exami-nation, her blood pressure is 130/89 mm Hg with a pulse of 50 bpm. Her weight is 136 lb (61.8 kg), an increase of 10 lb (4.5 kg) in the last year. Her thyroid gland is not palpable and her reflexes are delayed. Laboratory findings include a thyroid-stimulating hormone (TSH) level of 24.9 \u03bcIU/mL"
        },
        {
            "id": "Pharmacology_Katzung_7061",
            "title": "Pharmacology_Katzung",
            "content": "A 53-year-old woman with a history of knee osteoarthritis, high cholesterol, type 2 diabetes, and hypertension presents with new onset of hot flashes and a question about a dietary supplement. She is obese (body mass index [BMI] 33), does not exercise, and spends a good portion of her work day in a seated position. She eats a low-sugar diet and regularly eats packaged frozen meals for dinner because she doesn\u2019t have time to cook regularly. Her most recent laboratory values include a low-density lipoprotein (LDL) cholesterol that is above goal at 160 mg/dL (goal < 100 mg/dL) and a hemo-globin A1c that is well controlled at 6%. Her blood pressure is high at 160/100 mm Hg. Her prescription medications include simvastatin, metformin, and benazepril. She also takes over-the-counter ibuprofen for occasional knee pain and a multivitamin supplement once daily. She has heard good things about natural products and asks you if taking a garlic supplement daily could help to bring her blood"
        },
        {
            "id": "Pathology_Robbins_1082",
            "title": "Pathology_Robbins",
            "content": "Despite these dramatic improvements, several new complications associated with HIV infection and its treatment have emerged. Some patients with advanced disease who are given anti-retroviral therapy develop a paradoxical clinical deterioration during the period of recovery of the immune system despite increasing CD4+ T-cell counts and decreasing viral load. This disorder, called the immune reconstitution inflammatory syndrome, is not understood but is postulated to be a poorly regulated host response to the high antigenic burden of persistent microbes. Perhaps a more important complication of long-term anti-retroviral therapy pertains to adverse side effects of the drugs. These include lipoatrophy (loss of facial fat), lipoaccumulation (excess fat deposition centrally), elevated lipids, insulin resistance, peripheral neuropathy, and premature cardiovascular, kidney, and liver disease. Finally, non-AIDS morbidity is far more common than classic AIDS-related morbidity in long-term"
        },
        {
            "id": "Gynecology_Novak_2929",
            "title": "Gynecology_Novak",
            "content": "Treatment Decisions regarding the initiation of antiretroviral therapy should be guided by monitoring the laboratory parameters of HIV RNA (viral load) and CD4+ T-cell count, and the clinical condition of the patient. The primary goals of antiretroviral therapy are maximal and durable suppression of viral load, restoration or preservation of immunologic function, improvement of quality of life, reduction of HIV-related morbidity and mortality, and prevention of HIV transmission. Antiretroviral therapy should be initiated in all women with a history of an AIDS-defining illness or with a CD4 count less than 350 cells per mm3 . Antiretroviral treatment should be started regardless of CD4 count in women with the following conditions: pregnancy, HIV-associated nephropathy, and hepatitis B coinfection when treatment of hepatitis B is indicated. Patients must be willing to accept therapy to avoid the emergence of resistance caused by poor compliance. Dual nucleoside regimens used in addition"
        },
        {
            "id": "InternalMed_Harrison_15406",
            "title": "InternalMed_Harrison",
            "content": "Treatment decisions must take into account the fact that one is dealing with a chronic infection that requires daily therapy. While early therapy is generally the rule in infectious diseases, immediate treatment of every HIV-infected individual upon diagnosis may not be prudent, and therapeutic decisions must take into account the balance between risks and benefits. Patients initiating antiretroviral therapy must be willing to commit to life-long treatment and understand the importance of adherence to their prescribed regimen. The importance of adherence is illustrated by the observation that treatment interruption is associated with rapid increases in HIV RNA levels, rapid declines in CD4+ T cell counts, and an increased risk of clinical progression. While it seems reasonable to assume that the complications associated with cART could be minimized by Human Immunodeficiency Virus Disease: AIDS and Related Disorders 1."
        },
        {
            "id": "InternalMed_Harrison_15124",
            "title": "InternalMed_Harrison",
            "content": "Human Immunodeficiency Virus Disease: AIDS and Related Disorders 1250 RNA levels. Patients with high levels of HIV RNA in plasma progress to symptomatic disease faster than do patients with low levels of HIV RNA (Fig. 226-22). Some patients referred to as long-term nonprogressors show little if any decline in CD4+ T cell counts over extended periods of time. These patients generally have extremely low levels of HIV RNA; a subset, referred to as elite nonprogressors, exhibits HIV RNA levels <50 copies/mL. Certain other patients remain entirely asymptomatic despite the fact that their CD4+ T cell counts show a steady progressive decline to extremely low levels. In these patients, the appearance of an opportunistic disease may be the first manifestation of HIV infection. During the asymptomatic period of HIV infection, the average rate of CD4+ T cell decline is ~50/\u03bcL per year. When the CD4+ T cell count falls to <200/\u03bcL, the resulting state of immunodeficiency is severe enough to place"
        },
        {
            "id": "Pharmacology_Katzung_1130",
            "title": "Pharmacology_Katzung",
            "content": "Irbesartan Generic,Avapro Treatment of Angina Pectoris Bertram G. Katzung, MD, PhD* A 56-year-old woman presents in the office with a history of recent-onset chest discomfort when jogging or swimming vigorously. The pain is dull but poorly localized; it disap-pears after 5\u201310 minutes of rest. She has never smoked but has a history of hyperlipidemia (total cholesterol level of 245 mg/dL and low-density lipoprotein [LDL] of 160 mg/dL recorded 1 year ago) and admits that she has not been fol-lowing the recommended diet. Her father survived a \u201cheart attack\u201d at age 55, and an uncle died of some cardiac disease at age 60. On physical examination, the patient\u2019s blood pressure is 145/90 mm Hg, and her heart rate is 80 bpm. She is in no acute distress, and there are no other significant physical findings; an electrocardiogram is normal except for slight left ventricular hypertrophy. Assuming that a diagno-sis of stable effort angina is correct, what medical treatment should be implemented?"
        },
        {
            "id": "InternalMed_Harrison_15417",
            "title": "InternalMed_Harrison",
            "content": "weeks. Prior to changing a treatment regimen because of drug failure, it is important to ensure that the patient has been adherent to the prescribed regimen. As in the case of initial therapy, the simpler the new therapeutic regimen, the easier it is for the patient to be compliant. Plasma HIV RNA levels should be monitored every 3\u20136 months during therapy and more frequently if one is contemplating a change in regimen due to an increase in viral load or immediately following a change in regimen."
        },
        {
            "id": "InternalMed_Harrison_15407",
            "title": "InternalMed_Harrison",
            "content": "Human Immunodeficiency Virus Disease: AIDS and Related Disorders 1. Ongoing HIV replication leads to immune system damage, progression to AIDS, and systemic immune activation. 2. Plasma HIV RNA levels indicate the magnitude of HIV replication and the rate of CD4+ T cell destruction. CD4+ T cell counts indicate the current level of competence of the immune system. 3. Maximal suppression of viral replication is a goal of therapy; the greater the suppression the less likely the appearance of drug-resistant quasispecies. 4. The most effective therapeutic strategies involve the simultaneous initiation of combinations of effective anti-HIV drugs with which the patient has not been previously treated and that are not cross-resistant with antiretroviral agents that the patient has already received. 5. The antiretroviral drugs used in combination regimens should be used according to optimum schedules and dosages. 6."
        },
        {
            "id": "InternalMed_Harrison_32564",
            "title": "InternalMed_Harrison",
            "content": "Many clinical laboratory tests offer useful information on the progress of disease and the response to therapy. One example is the measurement of viral load in HIV-1-infected patients who are taking antiretroviral agents. According to current guidelines from the Centers for Disease Control and Prevention, a successful antiretroviral response is defined by a fall in plasma HIV-1 levels of 0.5 log10 copies/mL, and a key goal of treatment is a reduction in the viral load to below the level of detection, which is typically in the range of 40\u201375 copies/mL. Other examples of the use of clinical laboratory testing for monitoring disease include measurement of tumor markers such as PSA, especially following surgical removal of tumors. In this situation, the expectation is that successful treatment of a tumor will cause a decrease in the level of the tumor marker. A later increase in the level of the tumor marker suggests a recurrence of the disease. Finally, the clinical laboratory offers"
        },
        {
            "id": "Pharmacology_Katzung_5118",
            "title": "Pharmacology_Katzung",
            "content": "A 45-year-old man with no significant medical history was admitted to the intensive care unit (ICU) 10 days ago after suffering third-degree burns over 40% of his body. He had been relatively stable until the last 24 hours. Now, he is febrile (39.5\u00b0C [103.1\u00b0F]), and his white blood cell count has risen from 8500 to 20,000/mm3. He has also had an episode of hypo-tension (86/50 mmHg) that responded to a fluid bolus. Blood cultures were obtained at the time of his fever and results are pending. The ICU attending physician is concerned about a bloodstream infection and decides to treat with empiric com-bination therapy directed against Pseudomonas aeruginosa. The combination therapy includes tobramycin. The patient weighs 70 kg (154 lb) and has an estimated creatinine clear-ance of 90 mL/min. How should tobramycin be dosed using once-daily and conventional dosing strategies? How should each regimen be monitored for efficacy and toxicity?"
        },
        {
            "id": "InternalMed_Harrison_8340",
            "title": "InternalMed_Harrison",
            "content": "The natural history of severe aplastic anemia is rapid deterioration and death. Historically, provision first of RBC and later of platelet transfusions and effective antibiotics were of some benefit, but few patients show spontaneous recovery. The major prognostic determinant is the blood count. Severe disease has been defined by the presence of two of three parameters: absolute neutrophil count <500/\u03bcL, platelet count <20,000/\u03bcL, and corrected reticulocyte count <1% (or absolute reticulocyte count <60,000/\u03bcL). In the era of effective immunosuppressive therapies, absolute numbers of reticulocytes (>25,000/\u03bcL) and lymphocytes (>1000/\u03bcL) may be better predictors of response to treatment and long-term outcome."
        },
        {
            "id": "Surgery_Schwartz_2490",
            "title": "Surgery_Schwartz",
            "content": "In appropriate candidates, pretransplant antiviral treatment with interferon-\u03b1 may be considered. However, after a kidney transplant, inter-feron treatment is not recommended because it is an immunos-timulant, and thus HIV may precipitate graft rejection.Thanks to the excellent outcomes of highly active anti-retroviral therapy (HAART), infection with HIV is no longer considered a contraindication to a kidney transplant. Kidney transplant candidates with HIV must have an undetectable HIV viral load and a CD4 lymphocyte count greater than 200/mm3; in addition, they must not have developed any opportunistic infection in the previous year.78Latent viral infections such as CMV and EBV are of par-ticular interest in the field of transplantation, given the risks of reactivation posttransplant and their detrimental effects on graft and patient survival. Knowing the CMV and EBV sero-logic status of the recipient and donor helps transplant pro-fessionals gauge the risk of immunosuppressive"
        },
        {
            "id": "Pharmacology_Katzung_5171",
            "title": "Pharmacology_Katzung",
            "content": "A 59-year-old woman presents to an urgent care clinic with a 4-day history of frequent and painful urination. She has had fevers, chills, and flank pain for the past 2 days. Her physician advised her to come immediately to the clinic for evaluation. In the clinic she is febrile (38.5\u00b0C [101.3\u00b0F]) but otherwise stable and states she is not experiencing any nausea or vomiting. Her urine dipstick test is positive for leukocyte esterase. Urinalysis and urine culture are ordered. Her past medical history is significant for three urinary tract infections in the past year. Each episode was uncom-plicated, treated with trimethoprim-sulfamethoxazole, and promptly resolved. She also has osteoporosis for which she takes a daily calcium supplement. The decision is made to treat her with oral antibiotics for a complicated urinary tract infection with close follow-up. Given her history, what would be a reasonable empiric antibiotic choice? Depending on the antibiotic choice are there potential drug"
        },
        {
            "id": "Pharmacology_Katzung_368",
            "title": "Pharmacology_Katzung",
            "content": "A 40-year-old woman presents to the emergency department of her local hospital somewhat disoriented, complaining of midsternal chest pain, abdominal pain, shaking, and vomiting for 2 days. She admits to having taken a \u201chandful\u201d of Lorcet (hydrocodone/acetaminophen, an opioid/nonopioid analgesic combination), Soma (carisoprodol, a centrally acting muscle relaxant), and Cymbalta (duloxetine HCl, an antidepressant/ antifibromyalgia agent) 2 days earlier. On physical examina-tion, the sclera of her eyes shows yellow discoloration. Labora-tory analyses of blood drawn within an hour of her admission reveal abnormal liver function as indicated by the increased indices: alkaline phosphatase 302 (41\u2013133),* alanine amino-transferase (ALT) 351 (7\u201356),* aspartate aminotransferase (AST) 1045 (0\u201335),* bilirubin 3.33 mg/dL (0.1\u20131.2),* and pro-thrombin time of 19.8 seconds (11\u201315).* In addition, plasma bicarbonate is reduced, and she has ~45% reduced glomerular filtration rate from the normal value"
        },
        {
            "id": "InternalMed_Harrison_11078",
            "title": "InternalMed_Harrison",
            "content": "barrier allows sufficient CSF penetration. A randomized controlled trial of cidofovir in HIV-associated PML also failed to show significant benefit. Because PML almost invariably occurs in immunocompromised individuals, any therapeutic interventions designed to enhance or restore immunocompetence should be considered. Perhaps the most dramatic demonstration of this is disease stabilization and, in rare cases, improvement associated with the improvement in the immune status of HIV-positive patients with AIDS following institution of HAART. In HIV-positive PML patients treated with HAART, 1-year survival is ~50%, although up to 80% of survivors may have significant neurologic sequelae. HIV-positive PML patients with higher CD4 counts (>300/\u03bcL) and low or nondetectable HIV viral loads have a better prognosis than those with lower CD4 counts and higher viral loads. Although institution of HAART enhances survival in HIV-positive PML patients, the associated immune reconstitution in"
        },
        {
            "id": "First_Aid_Step2_1368",
            "title": "First_Aid_Step2",
            "content": "Hemoglobin, plasma Mean corpuscular hemoglobin Platelet count Prothrombin time Reticulocyte count Sedimentation rate, erythrocyte (Westergren) Proteins, total 1\u20134 mg/dL 0.16\u20130.62 \u03bcmol/L 4500\u201311,0 00/mm3 4.5\u201311.0 109/L 54\u201362% 0.54\u20130.62 3\u20135% 0.03\u20130.05 1\u20133% 0.01\u20130.03 0\u20130.75% 0\u20130.0075 25\u201333% 0.25\u20130.33 3\u20137% 0.03\u20130.07 25.4\u201334.6 pg/cell 0.39\u20130.54 fmol/cell 150,000\u2013400,000/mm3 150\u2013400 109/L 11\u201315 seconds 11\u201315 seconds 0.5\u20131.5% of red cells 0.005\u20130.015 Male: 0\u201315 mm/h 0\u201315 mm/h Female: 0\u201320 mm/h 0\u201320 mm/h < 150 mg/24 h < 0.15 g/24 h"
        },
        {
            "id": "Pharmacology_Katzung_5601",
            "title": "Pharmacology_Katzung",
            "content": "A 65-year-old man undergoes cystoscopy because of the presence of microscopic hematuria in order to rule out urologic malignancy. The patient has mild dysuria and pyuria and empirically receives oral therapy with cip-rofloxacin for presumed urinary tract infection prior to the procedure and tolerates the procedure well. Approxi-mately 48 hours after the procedure, the patient presents to the emergency department with confusion, dysuria and chills. Physical exam reveals a blood pressure of 90/50, pulse of 120, temperature of 38.5\u00b0 C and respira-tory rate of 24. The patient is disoriented but the physical exam is otherwise unremarkable. Laboratory test shows WBC 24,000/mm3 and elevated serum lactate; urinalysis shows 300 WBC per high power field and 4+ bacteria. What possible organisms are likely to be responsible for the patient\u2019s symptoms? At this point, what antibiotic(s) would you choose for initial therapy of this potentially life-threatening infection?"
        },
        {
            "id": "Pharmacology_Katzung_5050",
            "title": "Pharmacology_Katzung",
            "content": "Camille E. Beauduy, PharmD, & Lisa G. Winston, MD motion tenderness is present. A first-catch urine specimen is obtained for chlamydia and gonorrhea nucleic acid amplifi-cation testing. A urine pregnancy test is also ordered as the patient reports she \u201cmissed her last period.\u201d Pending these results, the decision is made to treat her presumptively for chlamydial cervicitis. What are two potential treatment options for her possible chlamydial infection? How does her potential pregnancy affect the treatment decision? A 22-year-old woman presents to her college medical clinic complaining of a 2-week history of vaginal discharge. She denies any fever or abdominal pain but does report vaginal bleeding after sexual intercourse. When questioned about her sexual activity, she reports having vaginal intercourse, at times unprotected, with two men in the last 6 months. A pelvic examination is performed and is positive for muco-purulent discharge from the endocervical canal. No cervical"
        },
        {
            "id": "InternalMed_Harrison_14936",
            "title": "InternalMed_Harrison",
            "content": "t1/2 = 1.0 day Uninfected, activated Long-lived In untreated patients or in patients in whom therapy has not adequately controlled virus replication, after a variable period, usually measured in years, the CD4+ T cell count falls below a critical level (<200/\u03bcL) and the patient becomes highly susceptible to opportunistic disease (Fig. 226-17). For this reason, the CDC case definition of AIDS includes all HIV-infected individuals over 5 years of age with CD4+ T cell counts below this level (Table 226-2). Patients may experience constitutional signs and symptoms or may develop an opportunistic disease abruptly without any prior symptoms, although the latter scenario is unusual. The depletion of CD4+ T cells continues to be progressive and unrelenting in this phase. It is not CD4+ lymphocytes infected with defective viruses"
        },
        {
            "id": "InternalMed_Harrison_14919",
            "title": "InternalMed_Harrison",
            "content": "HIV disease. Throughout the often protracted course of chronic infection, virus replication can invariably be detected in untreated patients by widely available assays that measure copies of HIV RNA per milliliter of plasma. Levels of virus vary greatly in most untreated patients, ranging from several thousand to a few million copies of HIV RNA per milliliter of plasma. Studies using highly sensitive molecular techniques have demonstrated that even in certain"
        },
        {
            "id": "Pharmacology_Katzung_2047",
            "title": "Pharmacology_Katzung",
            "content": "Joshua M. Galanter, MD, & Homer A. Boushey, MD and respirations are 32/min. Her mother states that she has used her albuterol inhaler several times a day for the past 3 days and twice during the previous night. She took an additional two puffs on her way to the emergency department, but her mother states that \u201cthe inhaler didn\u2019t seem to be helping so I told her not to take any more.\u201d What emergency measures are indicated? How should her long-term management be altered? A 14-year-old girl with a history of asthma requiring daily inhaled corticosteroid therapy and allergies to house dust mites, cats, grasses, and ragweed presents to the emergency department in mid-September, reporting a recent \u201ccold\u201d com-plicated by worsening shortness of breath and audible inspi-ratory and expiratory wheezing. She appears frightened and refuses to lie down but is not cyanotic. Her pulse is 120 bpm,"
        },
        {
            "id": "Pharmacology_Katzung_6809",
            "title": "Pharmacology_Katzung",
            "content": "A 21-year-old woman comes with her parents to discuss therapeutic options for her Crohn\u2019s disease. She was diag-nosed with Crohn\u2019s disease 2 years ago, and it involves her terminal ileum and proximal colon, as confirmed by colonoscopy and small bowel radiography. She was initially treated with mesalamine and budesonide with good response, but over the last 2 months, she has had a relapse of her symptoms. She is experiencing fatigue, cramping, abdominal pains, and nonbloody diarrhea up to 10 times daily, and she has had a 15-lb weight loss. She has no other significant medical or surgical his-tory. Her current medications are mesalamine 2.4 g/d and budesonide 9 mg/d. She appears thin and tired. Abdominal examination reveals tenderness without guarding in the right lower quadrant; no masses are palpable. On perianal examination, there is no tenderness, fissure, or fistula. Her laboratory data are notable for anemia and elevated C-reactive protein. What are the options for immediate"
        }
    ],
    "scores": [
        0.03850010164843483,
        0.03067717420793834,
        0.02404041969407076,
        0.023375181249196998,
        0.02316849816849817,
        0.02201198545418563,
        0.020181793049933765,
        0.019419306184012067,
        0.01886960391633289,
        0.018812930577636458,
        0.018608274190756446,
        0.018089960886571055,
        0.01778093883357041,
        0.017778128950695322,
        0.017711598746081504,
        0.017588325652841783,
        0.017427884615384616,
        0.017242660720921593,
        0.016955114675671873,
        0.01695402298850575,
        0.016842847075405214,
        0.016807899712865046,
        0.016597796143250687,
        0.016476215785277703,
        0.01626123744050767,
        0.016061980347694634,
        0.015788224121557455,
        0.015483022477283597,
        0.014983109948785005,
        0.014968082764692935,
        0.014945652173913044,
        0.014904698581560284
    ]
}